Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:15 PM
Ignite Modification Date:
2025-12-24 @ 4:15 PM
NCT ID:
NCT06551766
Eligibility Criteria:
Inclusion Criteria:
1. Voluntarily participate in this clinical study and sign the informed consent;
2. Gender is not limited, age 18-75 years old;
3. The patient had symptoms and signs of chronic dacryocystitis, and the results of lacrimal passage irrigation suggested that the lower rush and return or upper rush and lower return, accompanied by mucous or purulent discharge reflux;
4. Lacrimal duct angiography suggests nasolacrimal duct obstruction without lacrimal canaliculi and/or duct obstruction.
Exclusion Criteria:
1. Age \< 18 or \> 75 years old;
2. Previous history of dacryocystonasal anastomosis;
3. Abnormal coagulation function;
4. Tumors of lacrimal passage, especially in patients with papilloma or malignant tumors;
5. in the acute dacryocystitis attack stage;
6. obvious scar constitution;
7. Complicated with serious nasal diseases, such as severe allergic rhinitis, chronic rhinosinusitis and nasal polyps, acute suppurative rhinosinusitis, severe atrophic rhinitis, and severe deviation of nasal septum;
8. Have serious heart, liver, kidney, lung and other basic diseases, can not tolerate general anesthesia;
9. Distance from the hospital, postoperative review is not convenient;
10. Participated in other clinical trials within the last 3 months;
11. Any medical history that the investigator determines may interfere with the test results or increase the patient's risk.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT06551766
Study Brief:
Protocol Section:
NCT06551766